Opiant Pharmaceuticals (OPNT) & Apellis Pharmaceuticals (APLS) Critical Contrast

Opiant Pharmaceuticals (NASDAQ: OPNT) and Apellis Pharmaceuticals (NASDAQ:APLS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares Opiant Pharmaceuticals and Apellis Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals 8.93% 42.44% 15.34%
Apellis Pharmaceuticals N/A N/A N/A

Insider and Institutional Ownership

3.2% of Opiant Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.9% of Apellis Pharmaceuticals shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Opiant Pharmaceuticals and Apellis Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Apellis Pharmaceuticals 0 0 4 0 3.00

Apellis Pharmaceuticals has a consensus target price of $27.00, suggesting a potential upside of 65.34%. Given Apellis Pharmaceuticals’ higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Opiant Pharmaceuticals.

Valuation and Earnings

This table compares Opiant Pharmaceuticals and Apellis Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $18.45 million 2.52 $6.58 million $0.42 53.43
Apellis Pharmaceuticals N/A N/A -$27.12 million ($0.80) -20.41

Opiant Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Opiant Pharmaceuticals beats Apellis Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply